主双股动脉旁路术相比腔内治疗在主髂动脉闭塞性疾病中远期耐久性更优
基于VQI与Medicare链接数据(2010-2019)比较主双股动脉旁路术(ABF)与腹股沟韧带以上腔内治疗(PVI)治疗主髂动脉闭塞性疾病的5年结局。共纳入4282例(ABF 931例,PVI 3351例),ABF组5年免于主要不良肢体事件生存(MALE-FS)为58.7%,PVI组为38.2%(P<.001),校正后ABF仍与更优结局独立相关(aHR 0.544,95%CI 0.474-0.626)。
要点
- ABF组5年MALE-FS为58.7%,显著高于PVI组的38.2%(P<.001)。
- 校正后ABF与更优MALE-FS独立相关(aHR 0.544,95%CI 0.474-0.626,P<.001)。
- 在CLTI患者中ABF与更低的重大截肢或死亡风险独立相关(aHR 0.681,95%CI 0.533-0.870,P=.002)。
核心结论
- 尽管主髂动脉闭塞性疾病治疗持续向腔内优先转变,腹股沟韧带以上PVI的耐久性在长期可能无法维持。
- 在医学上合适的患者中,ABF可能为CLTI患者提供更好的保肢效果,而间歇性跛行患者可能经历更低的再干预率。
研究设计与样本
- 回顾性队列研究,查询Vascular Quality Initiative数据集并与Medicare索赔数据链接(2010-2019)。
- 纳入新发主髂动脉干预(ABF或腹股沟韧带以上PVI),排除急诊病例。
- 共识别4282例,其中ABF 931例(21.7%),PVI 3351例(78.2%;8.8%同期行股动脉内膜剥脱术)。
主要发现
- PVI使用率随时间增加(2010-2014年32.2%;2015-2019年67.8%;P=.011)。
- ABF组5年MALE-FS为58.7%,PVI组为38.2%(P<.001)。
- 校正后ABF与更优MALE-FS独立相关(aHR 0.544;95%CI 0.474-0.626;P<.001),在跛行(aHR 0.562;95%CI 0.466-0.679;P<.001)和CLTI(aHR 0.532;95%CI 0.434-0.652;P<.001)亚组中均一致。
- ABF组5年AFS为70.5%,PVI组为60.1%(P<.001);免于再干预生存分别为59.0%和38.4%(P<.001)。
- CLTI患者中ABF组生存率更高(66.4% vs 44.6%;P<.001);亚组分析中ABF仅与CLTI患者重大截肢或死亡风险降低独立相关(aHR 0.681;95%CI 0.533-0.870;P=.002)。
临床怎么用
- 对于医学上合适的CLTI患者,ABF可能提供更好的保肢效果,应考虑其作为治疗选择。
- 对于间歇性跛行患者,ABF可能降低再干预率,但需结合患者整体状况个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral endovascular intervention (PVI) has become a first-line treatment for aortoiliac occlusive disease. Although short- and mid-term data for PVI is strong, long-term comparative efficacy and durability of these interventions compared with aortobifemoral bypass (ABF) have not been well studied beyond single-institutional experiences. METHODS: Vascular Quality Initiative datasets were queried for de novo aortoiliac interventions (ABF or suprainguinal PVI) and linked to Medicare claims (2010-2019) (Vascular Quality Initiative and Vascular Implant Surveillance and Interventional Outcomes Network). Emergent cases were excluded. Primary outcome was 5-year estimates of major adverse limb event-free survival (MALE-FS; freedom major amputation, reintervention or death). Secondary outcomes were 5-year estimates of major amputation-free survival (AFS; freedom from major amputation or death), reintervention-free survival (freedom from reintervention or death), and survival. Kaplan-Meier analysis compared outcomes between ABF vs PVI. Adjusted analysis was performed using Cox regression. Subgroup analysis compared patients presenting with chronic limb-threatening ischemia (CLTI) vs claudication. RESULTS: We identified 4282 cases, including 931 ABF (21.7%) and 3351 PVI (78.2%; 8.8% with concurrent femoral endarterectomy). Overall, there was increased PVI utilization (2010-2014: 32.2%; 2015-2019: 67.8%; P = .011). Patients undergoing PVI were more likely to be older, live in urban areas, have higher rates of comorbidities, and present with claudication (68.1% vs 58.3%; P < .001). Five-year MALE-FS was 58.7% in the ABF group and 38.2% in the PVI (P < .001). The difference in rates of MALE and death favoring ABF persisted in adjusted analysis [adjusted hazard ratio (aHR), 0.544; 95% confidence interval (CI), 0.474-0.626; P < .001]. This remained true for patients treated for both claudication (aHR, 0.562; 95% CI, 0.466-0.679; P < .001) and CLTI (aHR, 0.532; 95% CI, 0.434-0.652; P < .001). Five-year AFS was 70.5% among patients undergoing ABF and 60.1% among patients with PVI (P < .001), whereas reintervention-free survival was 59.0% and 38.4%, respectively (P < .001). Survival was also greater with ABF among patients presenting with CLTI (66.4% vs 44.6%; P < .001). On subgroup analysis, ABF was independently associated with reduced risk of major amputation or death only among patients with CLTI (aHR, 0.681; 95% CI, 0.533-0.870; P = .002). There was no difference in AFS between ABF and PVI in patients with claudication, suggesting the reduced MALE-FS in patients undergoing PVI for claudication is driven by higher reintervention rates. CONCLUSIONS: Despite a continued temporal shift toward an endovascular-first approach for aortoiliac occlusive disease, durability of suprainguinal PVI may not persist long-term. In medically appropriate patients, ABF may offer patients with CLTI improved limb preservation, whereas patients with claudication may experience reduced rates of reintervention.
引用
- Yehualashet E, Olivere L, Zheng X, et al. Aortobifemoral bypass remains more durable long-term compared to endovascular intervention for aortoiliac occlusive disease. J Vasc Surg. 2026. PMID: 42476201. doi:10.1016/j.jvs.2026.06.162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。